BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 99 hits of ph data with Target = 'Glucagon'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Glucagon


(Homo sapiens (Human))
BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

5.75n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

7.60n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142039
PNG
(US8927577, 118 | US8927577, 20 | US8927577, 35)
Show SMILES Cc1cc2cc(F)ccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H30FN3O3/c1-16-12-19-13-21(28)8-9-22(19)30-25(16)31-24(20-14-27(2,3)15-20)17-4-6-18(7-5-17)26(34)29-11-10-23(32)33/h4-9,12-13,20,24H,10-11,14-15H2,1-3H3,(H,29,34)(H,30,31)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

14n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

15.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100796
PNG
(US8507533, 101)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

17n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

20.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142041
PNG
(US8927577, 22)
Show SMILES CC1(C)CC(C1)C(Nc1cnc2cc(F)ccc2c1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28FN3O3/c1-26(2)13-19(14-26)24(30-21-11-18-7-8-20(27)12-22(18)29-15-21)16-3-5-17(6-4-16)25(33)28-10-9-23(31)32/h3-8,11-12,15,19,24,30H,9-10,13-14H2,1-2H3,(H,28,33)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

25n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

25.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100850
PNG
(US8507533, 168)
Show SMILES CC(C)C[C@@H](Nc1ccc(cn1)C(=O)NCCC(O)=O)c1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C26H30F3N5O3/c1-15(2)9-21(33-22-6-5-18(12-31-22)25(37)30-8-7-23(35)36)19-10-16(3)24(17(4)11-19)34-14-20(13-32-34)26(27,28)29/h5-6,10-15,21H,7-9H2,1-4H3,(H,30,37)(H,31,33)(H,35,36)/t21-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

27.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100852
PNG
(US8507533, 170 | US8507533, 419)
Show SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1
Show InChI InChI=1S/C27H30F3N5O3/c1-16-11-20(12-17(2)25(16)35-15-21(14-33-35)27(28,29)30)24(18-5-3-4-6-18)34-22-8-7-19(13-32-22)26(38)31-10-9-23(36)37/h7-8,11-15,18,24H,3-6,9-10H2,1-2H3,(H,31,38)(H,32,34)(H,36,37)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

28n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

29n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

29.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100838
PNG
(US8507533, 153)
Show SMILES CCCC(Oc1cc(C)c(c(OC)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O5/c1-4-5-21(17-6-8-18(9-7-17)25(35)30-11-10-23(33)34)37-20-12-16(2)24(22(13-20)36-3)32-15-19(14-31-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

32.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100837
PNG
(US8507533, 152)
Show SMILES Cc1cc(OC(C2CC(C)(C)C2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C29H32F3N3O4/c1-17-11-23(12-18(2)25(17)35-16-22(15-34-35)29(30,31)32)39-26(21-13-28(3,4)14-21)19-5-7-20(8-6-19)27(38)33-10-9-24(36)37/h5-8,11-12,15-16,21,26H,9-10,13-14H2,1-4H3,(H,33,38)(H,36,37)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

35.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100805
PNG
(US8507533, 113)
Show SMILES CCCC(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C22H23F3N6O3/c1-2-3-18(14-4-6-15(7-5-14)20(34)26-9-8-19(32)33)30-17-11-27-21(28-12-17)31-13-16(10-29-31)22(23,24)25/h4-7,10-13,18,30H,2-3,8-9H2,1H3,(H,26,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

38.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142039
PNG
(US8927577, 118 | US8927577, 20 | US8927577, 35)
Show SMILES Cc1cc2cc(F)ccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H30FN3O3/c1-16-12-19-13-21(28)8-9-22(19)30-25(16)31-24(20-14-27(2,3)15-20)17-4-6-18(7-5-17)26(34)29-11-10-23(32)33/h4-9,12-13,20,24H,10-11,14-15H2,1-3H3,(H,29,34)(H,30,31)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

39n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100861
PNG
(US8507533, 188)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

42.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100864
PNG
(US8507533, 193)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
44.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100815
PNG
(US8507533, 122)
Show SMILES CC(C)(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C28H35N5O3/c1-28(2,3)23-17-33(18-31-23)24-13-12-22(16-30-24)32-26(19-6-4-5-7-19)20-8-10-21(11-9-20)27(36)29-15-14-25(34)35/h8-13,16-19,26,32H,4-7,14-15H2,1-3H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

45.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

47.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2229
PNG
(US8507533, 187 | US8507533, 448)
Show SMILES CCC[C@H](Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)/t26-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

47.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142042
PNG
(US8927577, 23)
Show SMILES CC1(C)CC(C1)C(Nc1cnc2ccc(F)cc2c1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28FN3O3/c1-26(2)13-19(14-26)24(30-21-12-18-11-20(27)7-8-22(18)29-15-21)16-3-5-17(6-4-16)25(33)28-10-9-23(31)32/h3-8,11-12,15,19,24,30H,9-10,13-14H2,1-2H3,(H,28,33)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

50n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100824
PNG
(US8507533, 131)
Show SMILES Cc1cc(OC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cnc(c1)C(F)(F)F
Show InChI InChI=1S/C28H30F3N3O4/c1-17-13-22(14-18(2)25(17)34-15-23(33-16-34)28(29,30)31)38-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(37)32-12-11-24(35)36/h7-10,13-16,19,26H,3-6,11-12H2,1-2H3,(H,32,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

51n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142038
PNG
(US8927577, 117 | US8927577, 19 | US8927577, 32)
Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

53n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100801
PNG
(US8507533, 109 | US8507533, 322)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1F)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H23F4N5O3/c1-2-3-19(17-6-4-14(10-18(17)24)22(35)28-9-8-21(33)34)31-16-5-7-20(29-12-16)32-13-15(11-30-32)23(25,26)27/h4-7,10-13,19,31H,2-3,8-9H2,1H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

57.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100826
PNG
(US8507533, 133)
Show SMILES CCCC(Oc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H28N4O4/c1-2-6-25(21-9-11-22(12-10-21)28(35)29-16-15-27(33)34)36-24-13-14-26(30-18-24)32-19-23(17-31-32)20-7-4-3-5-8-20/h3-5,7-14,17-19,25H,2,6,15-16H2,1H3,(H,29,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

58n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100831
PNG
(US8507533, 144)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H33N3O4/c1-4-5-25(21-8-10-22(11-9-21)28(34)29-13-12-26(32)33)35-24-14-18(2)27(19(3)15-24)31-17-23(16-30-31)20-6-7-20/h8-11,14-17,20,25H,4-7,12-13H2,1-3H3,(H,29,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

62.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100829
PNG
(US8507533, 140)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(Cl)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26ClN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-11-9-22(10-12-23)31-17-20-16-21(28)8-13-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

62.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100847
PNG
(US8507533, 163)
Show SMILES Cc1nn(cc1Cl)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C25H28ClN5O3/c1-16-21(26)15-31(30-16)22-11-10-20(14-28-22)29-24(17-4-2-3-5-17)18-6-8-19(9-7-18)25(34)27-13-12-23(32)33/h6-11,14-15,17,24,29H,2-5,12-13H2,1H3,(H,27,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
65.9n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100797
PNG
(US8507533, 105)
Show SMILES CC(C)CC(Nc1cnc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28F3N5O3/c1-15(2)10-21(17-4-6-18(7-5-17)24(36)29-9-8-22(34)35)32-20-11-16(3)23(30-13-20)33-14-19(12-31-33)25(26,27)28/h4-7,11-15,21,32H,8-10H2,1-3H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

69.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100799
PNG
(US8507533, 107)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CC1CC1)Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)21-8-7-19(13-29-21)31-20(11-15-1-2-15)16-3-5-17(6-4-16)23(35)28-10-9-22(33)34/h3-8,12-15,20,31H,1-2,9-11H2,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

71.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142038
PNG
(US8927577, 117 | US8927577, 19 | US8927577, 32)
Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

74n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142030
PNG
(US8927577, 11 | US8927577, 30 | US8927577, 31)
Show SMILES CC(C)CC(Nc1nc2ccccc2cc1C)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H29N3O3/c1-16(2)14-22(28-24-17(3)15-20-6-4-5-7-21(20)27-24)18-8-10-19(11-9-18)25(31)26-13-12-23(29)30/h4-11,15-16,22H,12-14H2,1-3H3,(H,26,31)(H,27,28)(H,29,30)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

76n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100856
PNG
(US8507533, 181)
Show SMILES CC(C)(C)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26F3N5O3/c1-23(2,3)21(15-4-6-16(7-5-15)22(35)28-11-10-20(33)34)31-17-8-9-19(29-12-17)32-13-18(30-14-32)24(25,26)27/h4-9,12-14,21,31H,10-11H2,1-3H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

87.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100816
PNG
(US8507533, 123)
Show SMILES CC(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C27H33N5O3/c1-18(2)23-16-32(17-30-23)24-12-11-22(15-29-24)31-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(35)28-14-13-25(33)34/h7-12,15-19,26,31H,3-6,13-14H2,1-2H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

88.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100830
PNG
(US8507533, 141)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-21(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-20-12-16(2)24(17(3)13-20)32-14-22(31-15-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

89.5n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142035
PNG
(US8927577, 16)
Show SMILES CC(C)CC(Nc1ccc2cc(ccc2n1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H26F3N3O3/c1-15(2)13-21(16-3-5-17(6-4-16)24(34)29-12-11-23(32)33)31-22-10-7-18-14-19(25(26,27)28)8-9-20(18)30-22/h3-10,14-15,21H,11-13H2,1-2H3,(H,29,34)(H,30,31)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

91n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100798
PNG
(US8507533, 106)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCC1
Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)20-9-8-19(13-29-20)31-22(15-2-1-3-15)16-4-6-17(7-5-16)23(35)28-11-10-21(33)34/h4-9,12-15,22,31H,1-3,10-11H2,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

91.9n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100794
PNG
(US8507533, 300 | US8507533, 97 | US8507533, 98)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C25H26F3N5O3/c26-25(27,28)20-14-33(15-31-20)21-10-9-19(13-30-21)32-23(16-3-1-2-4-16)17-5-7-18(8-6-17)24(36)29-12-11-22(34)35/h5-10,13-16,23,32H,1-4,11-12H2,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

93n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100823
PNG
(US8507533, 130 | US8507533, 369)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(Cl)cn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28ClN3O4/c1-4-5-22(18-6-8-19(9-7-18)25(32)27-11-10-23(30)31)33-21-12-16(2)24(17(3)13-21)29-15-20(26)14-28-29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,27,32)(H,30,31)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

93.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100818
PNG
(US8507533, 125)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cccc(C)c2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-5-25(20-8-10-21(11-9-20)28(34)29-17-16-26(32)33)35-24-14-12-23(13-15-24)31-18-22-7-4-6-19(2)27(22)30-31/h4,6-15,18,25H,3,5,16-17H2,1-2H3,(H,29,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

98.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100854
PNG
(US8507533, 176)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H29N5O3/c1-2-3-22(18-6-8-19(9-7-18)25(33)26-13-12-24(31)32)29-21-10-11-23(27-15-21)30-16-20(14-28-30)17-4-5-17/h6-11,14-17,22,29H,2-5,12-13H2,1H3,(H,26,33)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

101n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142030
PNG
(US8927577, 11 | US8927577, 30 | US8927577, 31)
Show SMILES CC(C)CC(Nc1nc2ccccc2cc1C)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H29N3O3/c1-16(2)14-22(28-24-17(3)15-20-6-4-5-7-21(20)27-24)18-8-10-19(11-9-18)25(31)26-13-12-23(29)30/h4-11,15-16,22H,12-14H2,1-3H3,(H,26,31)(H,27,28)(H,29,30)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

101n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100812
PNG
(US8507533, 119)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Oc1ccc(cc1)-n1cc2ccccc2n1)C1CCCC1
Show InChI InChI=1S/C29H29N3O4/c33-27(34)17-18-30-29(35)22-11-9-21(10-12-22)28(20-5-1-2-6-20)36-25-15-13-24(14-16-25)32-19-23-7-3-4-8-26(23)31-32/h3-4,7-16,19-20,28H,1-2,5-6,17-18H2,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

103n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100817
PNG
(US8507533, 124)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H27N3O4/c1-2-5-25(19-8-10-20(11-9-19)27(33)28-17-16-26(31)32)34-23-14-12-22(13-15-23)30-18-21-6-3-4-7-24(21)29-30/h3-4,6-15,18,25H,2,5,16-17H2,1H3,(H,28,33)(H,31,32)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

109n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM142037
PNG
(US8927577, 18)
Show SMILES CC(C)CC(Nc1cnc2ccccc2c1C)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H29N3O3/c1-16(2)14-22(28-23-15-27-21-7-5-4-6-20(21)17(23)3)18-8-10-19(11-9-18)25(31)26-13-12-24(29)30/h4-11,15-16,22,28H,12-14H2,1-3H3,(H,26,31)(H,29,30)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

109n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...


US Patent US8927577 (2015)


BindingDB Entry DOI: 10.7270/Q29S1PRV
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100860
PNG
(US8507533, 187 | US8507533, 189 | US8507533, 450)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

109n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100823
PNG
(US8507533, 130 | US8507533, 369)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(Cl)cn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28ClN3O4/c1-4-5-22(18-6-8-19(9-7-18)25(32)27-11-10-23(30)31)33-21-12-16(2)24(17(3)13-21)29-15-20(26)14-28-29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,27,32)(H,30,31)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

116n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100833
PNG
(US8507533, 148)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(nn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H27F3N4O4/c1-4-5-20(17-6-8-18(9-7-17)24(35)29-11-10-22(33)34)36-19-12-15(2)23(16(3)13-19)32-14-21(30-31-32)25(26,27)28/h6-9,12-14,20H,4-5,10-11H2,1-3H3,(H,29,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
125n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100825
PNG
(US8507533, 132)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cn1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H28N6O3/c1-2-6-24(23-11-9-20(15-29-23)27(36)28-14-13-26(34)35)32-22-10-12-25(30-17-22)33-18-21(16-31-33)19-7-4-3-5-8-19/h3-5,7-12,15-18,24,32H,2,6,13-14H2,1H3,(H,28,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

132n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 99 total )  |  Next  |  Last  >>
Jump to: